histogenics
-
Biologics
Histogenics Corporation and Collagen Solutions plc Establish Supply Agreement
WALTHAM, Mass., Sept. 16, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing…
Read More » -
Recon
Histogenics Corporation Announces Dr. Gloria Matthews as Chief Medical Officer
WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Financial
Analysts Give Average Recommendation of “Buy” to Histogenics Corp (NASDAQ:HSGX)
By John Miller Shares of Histogenics Corp (NASDAQ:HSGX) have been given a consensus broker rating score of 1.50 (Buy) from…
Read More » -
Biologics
An unmet need for knees: Biotech Histogenics sets terms for $60 million IPO
Histogenics, a biotech developing a therapy for repairing knee cartilage using its tissue repair platform, announced terms for its IPO…
Read More » -
Financial
Histogenics Files for IPO
Histogenics Corp. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering…
Read More » -
Histogenics Reports Positive Phase 2 Data for NeoCart Autologous Cartilage Tissue Implant for the Treatment of Knee Cartilage Injury
WALTHAM, Mass.–(BUSINESS WIRE)–Histogenics Corporation, a privately held regenerative medicine company, today announced the presentation of positive Phase 2 data for…
Read More »